Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Angiogenesis is the process through which new blood vessels are formed from pre-existing
ones. Exosomes are involved in angiogenesis in cancer progression by transporting …

Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been
validated as a target in several tumour types through randomised trials, incorporating …

When Folkman first suggested a theory about the association between angiogenesis and
tumor growth in 1971, the hypothesis of targeting angiogenesis to treat cancer was formed …

Background The cardiovascular risk of angiogenesis inhibitors is not well-quantified. We
hypothesized that, compared to direct vascular endothelial growth factor (VEGF) inhibitors …

Purpose Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial
growth factor receptors, and has shown activity in men with previously treated metastatic …

Prostate cancer is the most commonly diagnosed cancer among men in the Western world.
Although localized disease can be effectively treated with established surgical and …

The development of targeted therapies has revolutionized cancer treatment, offering
improved efficacy with reduced side effects compared with traditional chemotherapy. This …

Bone cancers are characterised by the development of tumour cells in bone sites,
associated with a dysregulation of their environment. In the last two decades, numerous …

The genomic, epigenetic and metabolic determinants of prostate cancer pathobiology have
been extensively studied in epithelial cancer cells. However, malignant cells constantly …